Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor.
By A. Porter, J. Sauer, M. Knierman, G. Becker, M. Berna, J. Bao, G. Nomikos, Petra A. Carter, F. Bymaster, Andrea Baker Leese and 1 more. Journal of Pharmacology and Experimental Therapeutics, 2002
634 citations recorded by the source corpus.
Subfields: Endocrine and Autonomic Systems, Pharmacology, Toxicology
View Paper: https://www.semanticscholar.org/paper/ab53846ea9f65d5a673d2e4552933c2a26409b00
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Endocrine and Autonomic Systems
In Pharmacology
In Toxicology
Citations in the corpus
- International Union of Basic and Clinical Pharmacology. LXXIX. Cannabinoid Receptors and Their Ligands: Beyond CB1 and CB2 (2010, background): “In one investigation, virodhamine was found to activate CB2 receptors and to exhibit either partial agonist or antagonist activity at CB1 receptors (Porter et al., 2002).”
- Cannabinoid CB2 receptors: immunohistochemical localization in rat brain. (2006, background): “…et al., 1993), isolation of endocannabinoids (eCBs) (Devane et al., 1992; Hanus et al., 2001; Mechoulam and Parker, 2003; Onaivi et al., in press; Porter et al., 2002; Sugiura et al., 1995; Tsou et al., 1998) and entourage ligands (Ben-Shabat et al., 1998), and functional identification of…”
- Stress-induced analgesia. (2009, neutral): “46 among others (Devane et al., 1992; Hanus et al., 2001; Huang et al., 2002; Mechoulam et al., 1995; Porter et al., 2002; Sugiura et al., 1995).”
- The emerging role of the endocannabinoid system in endocrine regulation and energy balance. (2006, neutral): “Specifically, these compounds are 2-arachidonoyl-glyceryl-ether (noladin ether) (92), O-arachidonoyl-ethanolamine (virodhamine) (93), N-arachidonoyl-dopamine (94), and possibly oleamide (95).”